Time-kill kinetics of antibiotics active against rapidly growing mycobacteria.
暂无分享,去创建一个
[1] D. van Soolingen,et al. Antimycobacterial Agents Differ with Respect to Their Bacteriostatic versus Bactericidal Activities in Relation to Time of Exposure, Mycobacterial Growth Phase, and Their Use in Combination , 2005, Antimicrobial Agents and Chemotherapy.
[2] Robert Horsburgh,et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.
[3] A. van Belkum,et al. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. , 2010, The Journal of antimicrobial chemotherapy.
[4] F. Drobniewski,et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study , 2013, European Respiratory Journal.
[5] J. Gaillard,et al. In vivo evaluation of antibiotic activity against Mycobacterium abscessus. , 2014, The Journal of infectious diseases.
[6] D. van Soolingen,et al. Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence , 2013, Expert review of anti-infective therapy.
[7] S. Shin,et al. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. , 2012, American journal of respiratory and critical care medicine.
[8] B. Markova,et al. Pharmacokinetic and pharmacodynamic approach for comparing two therapeutic regimens using amikacin , 1994, Antimicrobial Agents and Chemotherapy.
[9] O. Cars,et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. , 2002, International journal of antimicrobial agents.
[10] O. Cars,et al. Tissue concentrations: do we ever learn? , 2007, The Journal of antimicrobial chemotherapy.
[11] G. Bloemberg,et al. Lack of Antimicrobial Bactericidal Activity in Mycobacterium abscessus , 2014, Antimicrobial Agents and Chemotherapy.
[12] J. Zuckerman,et al. Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). , 2011, The Medical clinics of North America.
[13] C. Daley,et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. , 2012, American journal of respiratory and critical care medicine.
[14] J. Alffenaar,et al. Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. , 2013, International journal of antimicrobial agents.
[15] K. Greenwood-Quaintance,et al. Combinations of cefoxitin plus other β-lactams are synergistic in vitro against community associated methicillin-resistant Staphylococcus aureus , 2013, European Journal of Clinical Microbiology & Infectious Diseases.
[16] R. Wallace,,et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes , 2011 .